The Chinese registration and global marketing conditions of imatinib mesylate were indroduced in recent years.Through analyzing the listed market information and the global marketing data,the results were that the data of Chinese registered manufactures and the drugs had big marketing,and there were more than a dozen research enterprises,the growth rate was up 40% in recent six years,the market share of imatinib class increased to 21.27% in recent seven years.It was pointed out that the drug had a market prospect,and many pharmaceutical enterprises paid attention to it.